ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Filamentous-Actin-Mimicking Nanoplatform for Enhanced Cytosolic Protein Delivery.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A Glucose Metabolism-Modulatory Nanobiohybrid Vaccine Platform Promotes Anti-Tumor Immunity by Orchestrating Autophagy-Dependent Cross-Presentation and HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MXene-based CRISPR/Cas9 nanoplatform targeting FABP5 for ROS amplification and synergistic photothermal/photodynamic therapy of cervical cancer.Journal of nanobiotechnology · 2026Article
- Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics.Materials today. Bio · 2025Article
- Ferroptosis in organ ischemia-reperfusion injuries: recent advancements and strategies.Molecular and cellular biochemistry · 2025Review
- Bright NIR-II emissive cyanine dye-loaded lipoprotein-mimicking nanoparticles for fluorescence imaging-guided and targeted NIR-II photothermal therapy of subcutaneous glioblastoma.Journal of nanobiotechnology · 2024Article
- Highly stable and near-infrared responsive phase change materials for targeted enzyme delivery toward cancer therapy.Materials today. Bio · 2024Article
- Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances.Journal of nanobiotechnology · 2024Review
- Filamentous-Actin-Mimicking Nanoplatform for Enhanced Cytosolic Protein Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Despite the potential of protein therapeutics, the cytosolic delivery of proteins with high efficiency and bioactivity remains a significant challenge owing to exocytosis and lysosomal degradation after endocytosis. Therefore, it is important to develop a safe and efficient strategy to bypass endocytosis. Inspired by the extraordinary capability of filamentous-actin (F-actin) to promote cell membrane fusion, a cyanine dye assembly-containing nanoplatform mimicking the structure of natural F-actin is developed. The nanoplatform exhibits fast membrane fusion to cell membrane mimics and thus enters live cells through membrane fusion and bypasses endocytosis. Moreover, it is found to efficiently deliver protein cargos into live cells and quickly release them into the cytosol, leading to high protein cargo transfection efficiency and bioactivity. The nanoplatform also results in the superior inhibition of tumor cells when loaded with anti-tumor proteins. These results demonstrate that this fusogenic nanoplatform can be valuable for cytosolic protein delivery and tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.